• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

帕金森病治疗中“非运动期”结局的患者偏好与效用

Patient preferences and utilities for 'off-time' outcomes in the treatment of Parkinson's disease.

作者信息

Palmer C S, Schmier J K, Snyder E, Scott B

机构信息

MEDTAP International, Bethesda, Maryland 20814, USA.

出版信息

Qual Life Res. 2000;9(7):819-27. doi: 10.1023/a:1008903126315.

DOI:10.1023/a:1008903126315
PMID:11297024
Abstract

The purpose of this study was to derive patient preferences and utilities for outcomes associated with treatment of motor fluctuations, or 'off-time', for patients with Parkinson's disease (PD). Visual analog scale (VAS) and standard gamble (SG) approaches were used with 60 patients to determine patient preferences and utilities for 10 health state descriptions. Health state descriptions were categorized according to two factors: disease severity, and proportion of the day with 'off-time'. There were two representative levels of disease severity, based on Hoehn and Yahr stages 1.5 and 2.5: unilateral disease with no postural instability, and bilateral disease with some postural instability. These severity levels were combined with five levels of 'off-time' per day ranging from none to > 75% of the day. Patients' mean preference or utility for their own current health ranged from 0.65 +/- 0.20 (VAS) to 0.74 +/- 0.22 (SG). Patients assigned the lowest mean values to the health state description for Hoehn and Yahr stage 2.5 with 'off-time' for > 75% of the day (VAS: 0.17 +/- 0.17; SG: 0.49 +/- 0.27). The highest mean values were assigned to Hoehn and Yahr stage 1.5 with no 'off-time' (VAS: 0.83 +/- 0.17; SG: 0.85 +/- 0.18). The results of this study indicated patients with PD would likely seek treatment that would minimize the amount of 'off-time' experienced per day, and that patients were relatively risk averse.

摘要

本研究的目的是得出帕金森病(PD)患者对于与运动波动(即“关期”)治疗相关结局的偏好和效用值。对60名患者采用视觉模拟量表(VAS)和标准博弈法(SG),以确定患者对10种健康状态描述的偏好和效用值。健康状态描述根据两个因素进行分类:疾病严重程度和“关期”占一天的比例。基于Hoehn和Yahr分期的1.5期和2.5期,有两个具有代表性的疾病严重程度水平:无姿势不稳的单侧疾病,以及有一定姿势不稳的双侧疾病。这些严重程度水平与每天从无到超过一天75%的五个“关期”水平相结合。患者对自身当前健康状况的平均偏好或效用值范围为0.65±0.20(VAS)至0.74±0.22(SG)。患者对Hoehn和Yahr 2.5期且“关期”超过一天75%的健康状态描述赋予了最低平均值(VAS:0.17±0.17;SG:0.49±0.27)。最高平均值赋予了Hoehn和Yahr 1.5期且无“关期”的情况(VAS:0.83±0.17;SG:0.85±0.18)。本研究结果表明,PD患者可能会寻求能使每天经历的“关期”量最小化的治疗,并且患者相对厌恶风险。

相似文献

1
Patient preferences and utilities for 'off-time' outcomes in the treatment of Parkinson's disease.帕金森病治疗中“非运动期”结局的患者偏好与效用
Qual Life Res. 2000;9(7):819-27. doi: 10.1023/a:1008903126315.
2
Health-related quality of life in Parkinson's: impact of 'off' time and stated treatment preferences.帕金森病患者与健康相关的生活质量:“关”期的影响及明确的治疗偏好
Qual Life Res. 2016 Jun;25(6):1505-15. doi: 10.1007/s11136-015-1187-0. Epub 2015 Dec 1.
3
Preference-based measurement of health-related quality of life (HRQL) in children with chronic musculoskeletal disorders (MSKDs).基于偏好的慢性肌肉骨骼疾病(MSKDs)患儿健康相关生活质量(HRQL)测量
Med Decis Making. 2003 Jul-Aug;23(4):314-22. doi: 10.1177/0272989X03256008.
4
Cost effectiveness of treatment of Parkinson's disease with entacapone in the United States.在美国,恩他卡朋治疗帕金森病的成本效益。
Pharmacoeconomics. 2002;20(9):617-28. doi: 10.2165/00019053-200220090-00005.
5
Patient Utilities in Health States Based on Hoehn and Yahr and Off-Time in Parkinson's Disease: A Swedish Register-Based Study in 1823 Observations.基于 Hoehn 和 Yahr 量表和帕金森病停用时程的患者健康状态效用:一项瑞典基于登记的 1823 例观察研究。
Pharmacoeconomics. 2021 Oct;39(10):1141-1149. doi: 10.1007/s40273-021-01056-z. Epub 2021 Jul 7.
6
[Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].[司来吉兰在日常临床应用中。帕金森病患者联合治疗的研究结果]
Fortschr Neurol Psychiatr. 2008 Oct;76(10):594-9. doi: 10.1055/s-2008-1038249. Epub 2008 Oct 2.
7
Disease severity-based evaluation of utility weights for lung cancer-related health states in Korea.基于疾病严重程度的韩国肺癌相关健康状态效用权重评估。
BMC Cancer. 2018 Nov 8;18(1):1081. doi: 10.1186/s12885-018-4960-y.
8
Health State Utilities for Patient's Current Health from Bipolar Type I Disorder.双相I型障碍患者当前健康状况的健康状态效用值
J Ment Health Policy Econ. 2018 Mar 1;21(1):3-10.
9
Assessing the preferences of patients with psoriasis. A quantitative, utility approach.评估银屑病患者的偏好:一种定量效用方法。
Arch Dermatol. 1995 May;131(5):561-8.
10
Patients' health-related quality of life and utilities associated with different stages of amyotrophic lateral sclerosis.肌萎缩侧索硬化不同阶段患者的健康相关生活质量及效用
J Neurol Sci. 2001 Oct 15;191(1-2):87-93. doi: 10.1016/s0022-510x(01)00616-5.

引用本文的文献

1
Cost of Quality of Life in Advanced Parkinson's Disease: Efficient Strategies for Disease Assessment.晚期帕金森病的生活质量成本:疾病评估的有效策略
Rev Neurol. 2025 Jul 23;80(6):33482. doi: 10.31083/RN33482.
2
Economic Evaluations Comparing Deep Brain Stimulation to Best Medical Therapy for Movement Disorders: A Meta-Analysis.比较深部脑刺激与最佳药物治疗运动障碍的经济学评价:一项荟萃分析。
Pharmacoeconomics. 2024 Jan;42(1):41-68. doi: 10.1007/s40273-023-01318-y. Epub 2023 Sep 26.
3
Modelling the Cost Effectiveness of Treatments for Parkinson's Disease: An Updated Methodological Review.

本文引用的文献

1
Measurement of health state utilities for economic appraisal.用于经济评估的健康状态效用测量。
J Health Econ. 1986 Mar;5(1):1-30. doi: 10.1016/0167-6296(86)90020-2.
2
Patients' experiences of Parkinson's disease.
J Gerontol B Psychol Sci Soc Sci. 1998 Jul;53(4):P213-22. doi: 10.1093/geronb/53b.4.p213.
3
The health burdens of Parkinson's disease.帕金森病的健康负担。
Mov Disord. 1998 May;13(3):406-13. doi: 10.1002/mds.870130306.
帕金森病治疗的成本效益建模:方法学更新综述。
Pharmacoeconomics. 2023 Oct;41(10):1205-1228. doi: 10.1007/s40273-023-01289-0. Epub 2023 Jun 21.
4
The Cost Effectiveness of Levodopa-Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson's Disease in England.左旋多巴-卡比多巴肠凝胶治疗英国晚期帕金森病的成本效果。
Pharmacoeconomics. 2022 May;40(5):559-574. doi: 10.1007/s40273-022-01132-y. Epub 2022 Mar 21.
5
Defining Utility Values for Chorea Health States in Patients with Huntington's Disease.定义亨廷顿舞蹈症患者舞蹈病健康状态的效用值。
Adv Ther. 2022 Apr;39(4):1784-1793. doi: 10.1007/s12325-022-02046-z. Epub 2022 Feb 23.
6
Patient-Centered Identification of Meaningful Regulatory Endpoints for Medical Devices to Treat Parkinson's Disease.以患者为中心确定用于治疗帕金森病的医疗器械的有意义的监管终点
MDM Policy Pract. 2021 Jul 2;6(1):23814683211021380. doi: 10.1177/23814683211021380. eCollection 2021 Jan-Jun.
7
Patient Utilities in Health States Based on Hoehn and Yahr and Off-Time in Parkinson's Disease: A Swedish Register-Based Study in 1823 Observations.基于 Hoehn 和 Yahr 量表和帕金森病停用时程的患者健康状态效用:一项瑞典基于登记的 1823 例观察研究。
Pharmacoeconomics. 2021 Oct;39(10):1141-1149. doi: 10.1007/s40273-021-01056-z. Epub 2021 Jul 7.
8
The potential price and access implications of the cost-utility and budget impact methodologies applied by NICE in England and ICER in the US for a novel gene therapy in Parkinson's disease.英国国家卫生与临床优化研究所(NICE)以及美国临床和经济审评研究所(ICER)所采用的成本效用和预算影响方法,对一种用于治疗帕金森病的新型基因疗法在价格和可及性方面可能产生的影响。
J Mark Access Health Policy. 2018 Aug 6;6(1):1500419. doi: 10.1080/20016689.2018.1500419. eCollection 2018.
9
The Role of Condition-Specific Preference-Based Measures in Health Technology Assessment.条件特异性偏好测量在卫生技术评估中的作用。
Pharmacoeconomics. 2017 Dec;35(Suppl 1):33-41. doi: 10.1007/s40273-017-0546-9.
10
Health-related quality of life in Parkinson's: impact of 'off' time and stated treatment preferences.帕金森病患者与健康相关的生活质量:“关”期的影响及明确的治疗偏好
Qual Life Res. 2016 Jun;25(6):1505-15. doi: 10.1007/s11136-015-1187-0. Epub 2015 Dec 1.
4
The usefulness of the Functional Status Questionnaire and Medical Outcomes Study Short Form in Parkinson's disease research.功能状态问卷和医学结局研究简表在帕金森病研究中的效用。
Qual Life Res. 1998 May;7(4):279-90. doi: 10.1023/a:1024973611880.
5
Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.托卡朋抑制儿茶酚-O-甲基转移酶可减少帕金森病症状波动患者的“剂末现象”及左旋多巴需求量。
Neurology. 1998 May;50(5 Suppl 5):S46-53. doi: 10.1212/wnl.50.5_suppl_5.s46.
6
COMT inhibition: a new treatment strategy for Parkinson's disease.儿茶酚-O-甲基转移酶抑制:帕金森病的一种新治疗策略。
Neurology. 1998 May;50(5 Suppl 5):S3-14. doi: 10.1212/wnl.50.5_suppl_5.s3.
7
Health-related quality of life in Parkinson's disease: a study of outpatient clinic attenders.帕金森病患者与健康相关的生活质量:一项针对门诊就诊者的研究。
Mov Disord. 1997 Nov;12(6):916-22. doi: 10.1002/mds.870120613.
8
Pathophysiology, assessment, and treatment of Parkinson's disease.帕金森病的病理生理学、评估与治疗
Nurse Pract. 1997 Jul;22(7):76-8, 80, 85 passim.
9
Epidemiology of Parkinson's disease.帕金森病的流行病学
Neurol Clin. 1996 May;14(2):317-35. doi: 10.1016/S0733-8619(05)70259-0.
10
The response to levodopa in Parkinson's disease: imposing pharmacological law and order.
Ann Neurol. 1996 May;39(5):561-73. doi: 10.1002/ana.410390504.